华仁药业：关于参与京津冀“3+N”联盟部分西药和中成药带量联动接续采购中选的公告

Core Viewpoint - Huarun Pharmaceutical and its subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement project in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Company Participation - Huarun Pharmaceutical and its wholly-owned subsidiaries, Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huarun Pharmaceutical (Rizhao) Co., Ltd., actively engaged in the bidding process for the procurement project [1] - The project is identified as "LH-YD2025-1" and involves both Western medicine and traditional Chinese medicine [1] Group 2: Procurement Results - The Tianjin Pharmaceutical Procurement Center has announced the selection results, confirming that Huarun Pharmaceutical's products, including mixed sugar electrolyte injection, betahistine hydrochloride sodium injection, and hydroxyethyl starch 130/0.4 sodium chloride injection, have been chosen for this procurement [1]